LAB282: two years of drug discovery impact

LAB282, a unique funding-expertise hybrid model to accelerate Oxford therapeutics out of the lab and into the wider world, launched two years ago this month. When it was conceived, LAB282 was a unique concept to accelerate therapeutics research emerging from Oxford...

Read More

LAB282 celebrates a year of impact in Oxford

The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation. LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec,...

Read More

LAB282 – accelerating drug discovery at Oxford

Oxford University, Oxford University Innovation, Oxford Sciences Innovation and Evotec announce a new partnership to advance the development of next-generation medicines arising from Oxford research. Called ‘LAB282’, the partnership will provide a £13m fund, open...

Read More

Lab282 Partners